Kami Maddocks, MD
Hematology · Columbus, OHNPI 1689698284
Payments from drug & device makers
Across 286 payments — averaging $49,566 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$6M
- AbbVie$3.9M
- Acerta Pharma LLC$1.9M
- Pfizer$1.6M
- Seagen Inc.$335K
- ADC Therapeutics America, Inc.$258K
- plus $205K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 23 | $6,040,354 |
| AbbVie | 52 | $3,900,594 |
| Acerta Pharma LLC | 15 | $1,852,397 |
| Pfizer | 23 | $1,583,903 |
| Seagen Inc. | 11 | $334,932 |
| ADC Therapeutics America, Inc. | 44 | $258,144 |
| Otsuka Pharmaceutical Co., Ltd. | 9 | $27,741 |
| Lilly USA, LLC | 10 | $26,102 |
| Bristol Myers Squibb | 17 | $21,162 |
| Genentech USA, Inc. | 13 | $18,756 |
| Incyte Corporation | 17 | $17,594 |
| Merck | 4 | $15,135 |
| AstraZeneca | 10 | $13,865 |
| E.r. Squibb & Sons, L.L.C. | 6 | $12,859 |
| Eli Lilly | 4 | $10,009 |
| Genentech, Inc. | 3 | $6,625 |
| Morphosys AG | 3 | $6,478 |
| Genmab U.S., Inc. | 7 | $6,438 |
| Novartis | 2 | $4,964 |
| Astrazeneca UK Limited | 5 | $4,762 |
| Gilead | 2 | $3,590 |
| Beigene USA, Inc. | 2 | $2,275 |
| Daiichi Sankyo Inc. | 1 | $2,258 |
| Epizyme, Inc. | 1 | $1,688 |
| Beone Medicines USA, Inc. | 1 | $1,600 |
| Janssen Scientific Affairs, LLC | 1 | $1,515 |
How this compares
$14,175,740 in reported general payments places this provider in the 95th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Columbus
- Jennifer WoyachColumbus$406.1M
- Kerry RogersColumbus$39.6M
- Uma BorateColumbus$23.8M
- Naresh BummaColumbus$4.9M
- Narendranath EpperlaColumbus$3.6M
- Lapo AlinariColumbus$3.1M
- Spero CatalandColumbus$2.8M
- Seema BhatColumbus$2.7M
- Nicole GrieselhuberColumbus$2.5M
- David BondColumbus$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.